Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
Presenter: Stephen Kim (Manager QA Site Qualification)
Participants: Dr Liga, Dr Triantafyllou, Christopoulou A., Sagiadinou E., Kefala D., Parastatidou S., Tzourtzou A., Maniati S.
Την Τετάρτη 02 Φεβρουαρίου 2022 πραγματοποιήθηκε εκπαίδευση του προσωπικού που συμμετέχει στη Λευκαφαίρεση από την εταιρεία Kite Pharma. H εκπαίδευση...
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A.
Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with
myelodysplastic syndrome (MDS). Although less intense
therapies are being used more often in AML, the dichotomy between...
Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas
Due to fast spreading of SARS-CoV-2 a panel of experts of EBMT recommends the following guidelines for transplant units, recipients, and donors of hematopoietic cells. These guidelines will be updated when new information is...
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Christopoulou A., Sagiadinou E.
Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible...
In 2021 the BMT CTN held the 4th State of the Science Symposium
where the deliberations of 11 committees concerning major topics
pertinent to a particular disease, modality, or complication of
transplant, as well as two committees to consider clinical trial
design and inclusion,...
In the coronavirus disease 19 (COVID-19) pandemic era, the
number of haploidentical hematopoietic cell transplantations (HCTs)
with peripheral blood (PB) grafts increased significantly compared
with HCTs with bone marrow (BM) grafts, which may be associated
with adverse outcomes. We compared outcomes of HCT in...
The prognosis of patients with early relapsed or refractory
large B-cell lymphoma after the receipt of first-line
chemoimmunotherapy is poor. In this international, phase 3
trial, patients with large B-cell lymphoma that was refractory to
or had relapsed no more than 12 months after first-line
chemoimmunotherapy...
Oμιλητής: Καθ. Αλέξανδρος Σπυριδωνίδης, 21ο Πανελλήνιο Συνέδριο
Μεταμοσχεύσεων
The Practice Guidelines Committee of the American Society for
Transplantation and Cellular Therapy partnered with
its Transplant Infectious Disease Special Interest Group to update
its 2009 compendium-style infectious diseases guidelines for the
care of hematopoietic cell transplant (HCT) recipients. A new
approach was taken with...
Η Novartis
Oncology συνεχίζοντας τη δέσμευσή της να
συμβάλλει στην ιατρική εκπαίδευση και στην επιστημονική ενημέρωση
των επαγγελματιών υγείας, θα θέλαμε να σας ενημερώσουμε ότι το
Τμήμα Αιματολογίας
της Novartis συνεχίζει θα
παρέχει για τρίτη συνεχόμενη χρονιά στους επαγγελματίες υγείας τη
δυνατότητα να παρακολουθήσουν μέσω διαδικτύου την εικονική
συνάντηση Ειδικών με θέμα...
Standardizing Definitions of Hematopoietic Recovery, Graft
Rejection,
Graft Failure, Poor Graft Function, and Donor Chimerism in
Allogeneic
Hematopoietic Cell Transplantation: A Report on Behalf of the
American Society for Transplantation and Cellular Therapy
Presenter:Prof.Spyridonidis
Participants:Dr Liga, Dr Tsokanas
Transplantation in lower-risk myelodysplastic syndromes
Presenter:Prof.Spyridonidis
Participants:Dr Liga, Dr Tsokanas
An analysis integrating ELN 2017, NPM1 MRD and KB scores to
answer the question whether to transplant or
not.
Presenter:Prof.Spyridonidis
Participants:Dr Liga, Dr Tsokanas
Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic
cell transplantation (allo-HCT) has a dismal
prognosis. Ιt was found that T cells of patients relapsing with AML
after allo-HCT exhibited reduced glycolysis and
interferon-γ production. Functional studies in multiple mouse
models of leukemia showed that leukemia-derived
lactic...
A paradigm shift has recently
occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and
small-molecule drugs targeting specific signalling pathways, have
been joined by cellular immunotherapies based on T cell
engineering. The rapid adoption of novel, patient-specific cellular
therapies builds...
Presenter:Prof.Spyridonidis
Participants:Dr Liga, Dr Tsokanas
A study using lithium for epithelial regeneration in acute
GvHD was presented.
Presenter:Dr Liga
Participants:Prof.Spyridonidis, Dr Tsokanas
Rates of CLABSI are the same in internal jugular vein-and
subclavian vein-CVC after allogeneic HCTThe strongest risk factor
for local inflammation or fever are >6 neutropenic CVC-days·Time
to local inflammation is longer with CVC placed in the internal
jugular vein·CVC placed in the subclavian...
Real-life experience in Spain (Spanish Group of Lymphoma and
Bone Marrow Transplantation, GELTAMO). Efficacy and
safety of nivolumab in real-life for the treatment of R/R Hodgkin
lymphoma is comparable with that reported in clinical trials.·The
main reasons for nivolumab discontinuation were referral for
transplantation and disease...
In a cohort of 126 allogeneic HCT recipients transplanted 1-39
years ago,62% were seropositive/seroprotected for measles before
any vaccination since transplantation. The
seropositivity/seroprotection was associated with
myeloproliferative disorder, reduced intensity or non-myeloablative
conditioning and absence of acute grade>2 graft-versus-host
disease.·Our findings strongly support a systematic assessment...